Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 03:20 p.m. PT. The event will take place in Rancho Palos Verdes, CA. A live webcast will be available on the Company’s website, with an archived replay for 90 days. Repare specializes in cancer therapies using its SNIPRx® platform, focusing on genomic instability and DNA damage repair, and is currently developed leading products like camonsertib (RP-3500) and RP-6306.
Repare Therapeutics has entered a worldwide license and collaboration agreement with Roche for the development of camonsertib (RP-3500), a selective ATR inhibitor targeting specific tumors. Repare will receive a
Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in the virtual 2022 Guggenheim Synthetic Lethality Day on May 16, 2022, at 9:00 a.m. ET. Senior management will engage in a fireside chat, providing insights into their precision oncology strategies. Interested parties can access a live webcast via the Investor section on their website, with an archived replay available for 90 days post-event. Repare is known for its innovative SNIPRx® platform focusing on synthetic lethality in cancer therapeutics development.
Repare Therapeutics Inc. (Nasdaq: RPTX) reported significant advancements in its RP-3500 program and showcased promising clinical data from the Phase 1/2 TRESR Trial at the 2022 AACR Annual Meeting. The trial demonstrated a 75% clinical benefit rate (CBR) in advanced ovarian cancer patients and 43% CBR across various solid tumors. Financially, the company reported cash reserves of $311.7 million but registered a net loss of $34.8 million for Q1 2022, reflecting increased R&D expenses. Repare anticipates further updates on camonsertib’s potential later in the year.
Repare Therapeutics has announced promising preclinical data that positions RP-6306, a first-in-class PKMYT1 inhibitor, as a potential treatment for CCNE1-amplified cancers. This data was published in Nature and shows significant tumor growth inhibition in vivo. Currently in Phase 1 clinical trials, RP-6306 is being studied both as a monotherapy and in combination with gemcitabine and FOLFIRI for advanced solid tumors. The SNIPRx platform played a pivotal role in identifying this novel therapeutic target, underscoring Repare's innovative capabilities.
Repare Therapeutics presented promising results for its drug
Repare Therapeutics Inc. (Nasdaq: RPTX) announced comprehensive Phase 1 monotherapy data from its ongoing Phase 1/2 TRESR trial for RP-3500, an ATR inhibitor, to be presented at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. An oral presentation is scheduled for April 11, 2022, at 3:05 PM CT, led by Dr. Timothy Yap. The company will host a conference call to discuss these findings on the same day at 6:30 PM ET. Repare aims to highlight RP-3500's therapeutic potential and ongoing development plans.
Repare Therapeutics (NASDAQ: RPTX) announced that it will present clinical data from its Phase 1/2 TRESR trial of RP-3500 at the upcoming 2022 AACR Annual Meeting in New Orleans. The oral presentation, focusing on genomic determinants of response to RP-3500 in patients with DNA damage repair mutant tumors, is scheduled for April 11, 2022. Additionally, a poster will be presented on the SNiPDx panel, aimed at detecting DNA repair gene losses in tumor samples, on April 12, 2022. Repare’s SNIPRx® platform supports its precision therapeutics development.
Repare Therapeutics Inc. announced positive findings from its Phase 1/2 TRESR clinical trial of
The company plans to share updated data from 120 patients in the first half of the year, reinforcing expectations for the therapeutic potential of
Repare Therapeutics Inc. (RPTX) reported its financial results for Q4 and full year 2021, highlighting key advancements in its precision oncology pipeline. Notable progress includes the initiation of the RP-6306 program and the RP-3500 Phase 2 trial for solid tumors. By December 31, 2021, cash reserves stood at $341.9 million, sufficient for operations through 2023. R&D expenses surged to $90 million, reflecting increased development costs. The net loss was $106.9 million, or $2.83 per share, compared to $53.4 million, or $2.66 per share in 2020.
